RT Journal Article
SR Electronic
T1 Leprosy: a primer for Canadian physicians
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 71
OP 78
VO 170
IS 1
A1 Andrea K. Boggild
A1 Jay S. Keystone
A1 Kevin C. Kain
YR 2004
UL http://www.cmaj.ca/content/170/1/71.abstract
AB LEPROSY IS A RARE BUT SERIOUS INFECTIOUS DISEASE caused by Mycobacterium leprae. While global prevalence of the disease is decreasing, increasing rates of immigration from countries where leprosy is endemic have led to the recognition of this illness in North America. Classically, leprosy presents as hypopigmented cutaneous macules along with sensory and motor peripheral neuropathies, although the clinical manifestations vary along a disease spectrum. In addition to primary infection, patients may undergo a “reaction,” an acute inflammatory response to the mycobacterium, which leads to pain and erythema of skin lesions and dangerous neuritis. Reactions can occur at any time during the course of leprosy, but they tend to be precipitated by treatment. They are a significant cause of impaired quality of life due to marked nerve damage and thus warrant prompt intervention. Although leprosy may have a protracted onset and be difficult to recognize, cure is achievable with appropriate multidrug therapy. Because untreated leprosy can result in permanent, irreversible nerve damage and secondary transmission, early diagnosis and treatment are essential to minimize morbidity.